Phase 2, Phase 3 Recruiting NIH
This phase II/III trial examines whether patients who have undergone surgical removal of bladder, kidney, ureter or urethra, but require an additional treatment called immunotherapy to help prevent their urinary tract (urothelial) cancer f…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05987241
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Cancer Institute - Spartanburg — Boiling Springs, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
- Prisma Health Cancer Institute - Easley — Easley, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of decreased number of radiation (ultra-hypofractionated) treatments to the usual radiation number of treatments (hypofractionation) with standard of care chemotherapy, with cisplatin, gemcitabine o…
Sponsor: NRG Oncology
NCT ID: NCT07097142
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Self Regional Healthcare — Greenwood, South Carolina
- Gibbs Cancer Center-Pelham — Greer, South Carolina
- Spartanburg Medical Center — Spartanburg, South Carolina
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding gemcitabine to intravesical Bacillus Calmette Guerin (BCG) versus intravesical BCG alone in patients with non-muscle invasive bladder cancer that has come back after a period of improvemen…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07000084
Sites in South Carolina: - Ralph H Johnson VA Medical Center — Charleston, South Carolina
- Medical University of South Carolina — Charleston, South Carolina
Phase 3 Recruiting Industry
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06510374
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of intermediate-risk NMIBC.
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06319820
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The pivotal phase 3 trial (rAd-IFN-CS 003) evaluating the efficacy of nadofaragene firadenovec showed that 55 (53.4%) of 103 subjects with CIS ± high-grade Ta/T1 achieved a complete response (CR) at 3 months. In this trial, the safety and …
Sponsor: Ferring Pharmaceuticals
NCT ID: NCT06545955
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2, Phase 3 Recruiting Industry
This is a global, multicenter, randomized, open-label, Phase 2/3 study of Dato-DXd plus carboplatin or cisplatin versus gemcitabine plus carboplatin or cisplatin in participants with la/mUC who progressed during or after EV plus pembrolizu…
Sponsor: Daiichi Sankyo
NCT ID: NCT07129993
Sites in South Carolina: - Research Site — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Gué…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06919965
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 3 Recruiting Industry
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without c…
Sponsor: Fidia Farmaceutici s.p.a.
NCT ID: NCT05024773
Sites in South Carolina: - Medical University of South Carolina (MUSC) — Charleston, South Carolina
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 2 Recruiting Industry
This is a Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate the Safety and Efficacy of Cretostimogene Grenadenorepvec in Participants with High-Risk Non-Muscle-Invasive Bladder Cancer.
Sponsor: CG Oncology, Inc.
NCT ID: NCT06567743
Sites in South Carolina: - Charleston Area Medical Center — Charleston, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Lowcountry Urology (Solaris) — North Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
This study will evaluate the safety and efficacy of intravesical administration of EG-70 in the bladder and its effect on bladder tumors in patients with NMIBC. This study study consists of two phases; a Phase 1 dose-escalation to establis…
Sponsor: enGene, Inc.
NCT ID: NCT04752722
Sites in South Carolina: - Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
Phase 2 Recruiting Industry
TARA-002-101-Ph2 is an open-label study to investigate the safety and efficacy of intravesical instillation of TARA-002 in adults 18 years of age or older with high-grade CIS NMIBC (± Ta/T1). The purpose of this Phase 2 study (TARA-002-101…
Sponsor: Protara Therapeutics
NCT ID: NCT05951179
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
The purpose of the study in Part 1 (dose escalation) and in Part 2 (dose expansion) is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) and evaluate preliminary clinical efficacy. Part 3 (dose expansion) will confirm safety and pre…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT05316155
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Low Country Urology Clinics — North Charleston, South Carolina
Phase 2 Recruiting Industry
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Sponsor: Tyra Biosciences, Inc
NCT ID: NCT06995677
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
- Lowcounty Urology Clinics, P.A. — North Charleston, South Carolina
Phase 2 Recruiting Industry
This is a phase II, open-label, single-arm, multi-center Study conducted in Canada and the United States. Patients with Non-Muscle Invasive Bladder Cancer ("NMIBC") Carcinoma In-Situ ("CIS") (with or without resected papillary disease (Ta,…
Sponsor: Theralase® Technologies Inc.
NCT ID: NCT03945162
Sites in South Carolina: - Site 02-006 - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human (FIH), Phase 1/2a, multi center, open-label, single treatment, dose escalation and expansion study designed to determine the safety and tolerability of STM-416 in patients with bladder cancer.
Sponsor: SURGE Therapeutics
NCT ID: NCT05710848
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 2 Recruiting Federal
The purpose of this research is to determine whether bladder cancer monitoring can be improved by replacing some cystoscopy procedures with urine testing. Specifically, this study examines whether there are any differences in urinary sympt…
Sponsor: White River Junction Veterans Affairs Medical Center
NCT ID: NCT05796375
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1, Phase 2 Recruiting Industry
Researchers are looking for new ways to treat high-risk non-muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder and has not spread to the bladder muscle or outside of the bladder. I…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07222488
Sites in South Carolina: - Carolina Urologic Research Center ( Site 0006) — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-435 by itself or when it is combined with other standard medicines that treat cancer. LOXO-435 may be used to treat cancer of the cel…
Sponsor: Eli Lilly and Company
NCT ID: NCT05614739
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in South Carolina: - Medical University of South Carolina — Charleston, South Carolina
Phase 1 Recruiting Industry
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults wh…
Sponsor: Pfizer
NCT ID: NCT07206225
Sites in South Carolina: - Grand Strand Medical Center — Myrtle Beach, South Carolina
- AUC Urologists, LLC — Myrtle Beach, South Carolina
- Carolina Urologic Research Center, LLC — Myrtle Beach, South Carolina
- Parkway Surgery Center — Myrtle Beach, South Carolina
- Coastal Eye Group — Myrtle Beach, South Carolina
Phase 1 Recruiting Industry
The main objectives of this study are to determine the feasibility and safety of Belzupacap Sarotalocan (AU-011, bel-sar) treatment of bladder cancer utilizing focal injections with or without laser application.
Sponsor: Aura Biosciences
NCT ID: NCT05483868
Sites in South Carolina: - Carolina Urologic Research Center — Myrtle Beach, South Carolina
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in South Carolina: - AnMed Health Cancer Center — Anderson, South Carolina
- Prisma Health Richland Hospital — Columbia, South Carolina
- McLeod Regional Medical Center — Florence, South Carolina
- Gibbs Cancer Center-Gaffney — Gaffney, South Carolina
- Tidelands Georgetown Memorial Hospital — Georgetown, South Carolina